Head-to-head evidence
AADvac1 vs Bepranemab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Tau (monoclonal antibody) · full Alzheimer's Disease pipeline
AADvac1
Developed by Axon Neuroscience
NCT02579252 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 208 participants, with safety as its primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: August 2028 · NCT07167966 (registry estimate)
Bepranemab
Developed by UCB
NCT04867616 · Phase 2 · completed
The study randomized 466 participants to two bepranemab dose groups or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical endpoint was change in CDR-SB at Week 80, but whether this endpoint was met cannot be determined because results are not posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AADvac1's landscape · Bepranemab's landscape